Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C92575
http://purl.obolibrary.org/obo/NCIT_C92575
|
|---|---|
| Preferred Name | Onatasertib |
| Definitions |
An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers. |
|---|---|
| prefLabel | Onatasertib
|
| label | Onatasertib
|
| PDQ_Closed_Trial_Search_ID | 683644
|
| code | C92575
|
| prefixIRI | NCIT:C92575
|
| in_subset |
See more
See less
|
| Display_Name | Onatasertib
|
| Preferred_Name | Onatasertib
|
| FDA_UNII_Code | I8RA3543SY
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
mTOR Kinase Inhibitor CC-223
Onatasertib
|
| CAS_Registry | 1228013-30-6
|
| NCI_Drug_Dictionary_ID | 683644
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 683644
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2985184
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |